close
Fox News Flash top headlines are here. Check out what’s clicking on Foxnews.com.
AstraZeneca said on Friday its and Daiichi Sankyo’s cancer drug Enhertu was recommended by the European Medicines Agency’s human medicines committee as a monotherapy to treat patients with a type of non-small cell lung cancer (NSCLC).
The recommendation is based on the mid-stage data where Enhertu showed a confirmed objective response rate of 49% and a median duration of response of 16.8 months in patients previously treated for lung cancer.
EU INITIATES ASSESSMENT OF HUMAN AND LABOR RIGHTS IN BURMA
AstraZeneca’s cancer medicine Enhertu, a drug developed jointly with Japan’s Daiichi Sankyo, is pictured in an undated handout image obtained by Reuters on June 27, 2022. (AstraZeneca/Handout via REUTERS/File photo)
CLICK HERE TO GET THE FOX NEWS APP
The drug is already approved in the European Union as a treatment for patients with an advanced form of breast cancer.
Recommendations made by the human medicines committee will have to be formally approved by the European Commission.
Things like your name, home address, date of birth and even your Social Security number…
Most people never think about Android security updates until a headline like this appears. Suddenly,…
The next time you pull up to the drive-thru at Burger King, you may notice…
You may think you can spot a crypto scam from a mile away. But what…
The first Tesla Cybercab has officially rolled off the floor at Tesla Gigafactory Texas. And…
Smart glasses promise a future where technology blends into everyday life. You can ask a…